Sartorius Group
The Sartorius Group is a leading international partner of biopharmaceutical research and the industry. With innovative laboratory instruments and consumables, the Groups Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2018, the company earned sales revenue of some 1.6 billion euros. Currently, more than 8,100 people work at the Groups approximately 60 manufacturing and sales sites, serving customers around the globe.
Sartorius Opens New Center of Excellence for Bioanalytics in Ann Arbor
Manufacturing of instruments, consumables and reagents for cell and protein analysis Consolidation of existing sites and functions in Ann Arbor Overall investment of around $100m. 5 June 2024 -- Michigan, US -- The life sciences group Sartorius today opened its new Center of Excellence for bioanalytics in Ann Arbor, Michigan, US, two years after breaking...
Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA
Exploring advanced technologies to help bring novel therapies to patients faster Sartorius to leverage NVIDIA solutions used in live-cell imaging platforms in drug discovery, predictive design of manufacturing processes and more Future plans include the creation of foundational models based on Sartorius’ extensive and unique data sets, as well as new predictive AI models, tools,...
Sartorius Collaborates with Sanofi to Commercialise End-To-End Platform for Downstream Process Intensification
Sartorius selected as preferred partner for development and commercialisation of integrated and continuous biomanufacturing (ICB) platform Modular platform will combine highest flexibility with standardisation ICB supports lower resource consumption and higher productivity, enabling more affordable patient care and sustainable bioprocessing Collaboration demonstrates Sartorius’ leading position in the field of process intensification. 13 May 2024 --...
Sartorius and TheWell Bioscience Partner to Enable More Accurate Predictions in Drug Discovery
Collaboration to advance TheWell Bioscience animal-free hydrogel solutions for 3D cell models Solutions address shift from animal-based to more human-relevant organoid models, resulting in more accurate predictions in drug discovery Synergies with Sartorius bioanalytical lab instruments for cell imaging. 9 April 2024 -- GÖTTINGEN, Germany -- The life science group Sartorius and US-based startup TheWell...
Sartorius to Acquire Albumedix, Strengthening its Portfolio of Innovative Advanced Therapy Solutions
Gˆttingen, August 8, 2022: The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example...
Sartorius Acquires Cell Culture Specialist Xell AG
The life science company Sartorius, through its subgroup Sartorius Stedim Biotech, acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany. Xell AG develops, produces, and markets media and feed supplements for cell cultures, especially for manufacturing viral vectors that are used in gene therapeutics and vaccines
Sartorius Presents Annual Report for 2021
The life science group Sartorius today has presented its 2021 Annual Report. Besides providing detailed information on its business performance, as well as on innovations, acquisitions and sustainability initiatives, the company also confirms its preliminary figures for fiscal 2021, which had already been published on January 27, 2022.
Sartorius acquires filtration expert WaterSep BioSeparations
Transaction provides a complementary fit with Sartoriusí separation portfolio, adding innovative crossflow filtration units for easy-to-use bioprocessing devices Technology is especially suited to gene and cell therapy applications, vaccine production and intensified bioprocessing
Sartorius debuts the Intellicyt iQue3 at CYTO 2019
Sartorius will be showcasing the latest addition to its cellular analysis portfolio on booth #103 at this yearís CYTO conference and exhibition, with the launch of the Intellicyt iQue3. The event - which takes place in Vancouver, Canada, from June 22 to 26 - will give delegates the chance to explore a smarter way to...
Sartorius Supports the Development of the First Vaccine Candidate Against the Novel Coronavirus to Enter Clinical Trials
SHANGHAI, China, March 25, 2020 / B3C newswire / -- Sartorius, a leading international partner of life science research and the biopharmaceutical industry, has supported CanSino Biologics Inc. ('CanSinoBIO') and Maj. Gen. Chen Weiís team at the Institute of Bioengineering at the Academy of Military Medical Sciences ('Institute of Bioengineering') in China in their development...
Sartorius Corporation, Otto-Brenner-Straße 20, 37079 Goettingen, Germany
+49.551.308.0
